CN113827630A - Use of maca extract in preparation of medicine or food - Google Patents

Use of maca extract in preparation of medicine or food Download PDF

Info

Publication number
CN113827630A
CN113827630A CN202010510452.XA CN202010510452A CN113827630A CN 113827630 A CN113827630 A CN 113827630A CN 202010510452 A CN202010510452 A CN 202010510452A CN 113827630 A CN113827630 A CN 113827630A
Authority
CN
China
Prior art keywords
protecting
seh
benzyl
maca
methoxybenzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010510452.XA
Other languages
Chinese (zh)
Inventor
刘俊彦
汉默克·布鲁斯·杜普瑞
巴尼奇·博格丹
黄宋熙
莫里索·克里斯托弗
杨军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ba NiqiBogedan
Han MokeBulusiDupurui
Mo LisuoKelisituofu
Original Assignee
Ba NiqiBogedan
Han MokeBulusiDupurui
Mo LisuoKelisituofu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ba NiqiBogedan, Han MokeBulusiDupurui, Mo LisuoKelisituofu filed Critical Ba NiqiBogedan
Priority to CN202010510452.XA priority Critical patent/CN113827630A/en
Publication of CN113827630A publication Critical patent/CN113827630A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Polymers & Plastics (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses application of a maca extract in preparation of medicines or foods. According to the invention, macamide is extracted from maca, the extracted macamide is found to be a water-soluble epoxide hydrolase inhibitor, the inhibitor has multiple functions of resisting inflammation, relieving pain, reducing blood pressure and blood sugar, protecting cardiovascular, kidney and nervous systems and the like, and particularly the N-benzyl linoleamide has good anti-inflammatory and analgesic effects. The invention solves the problems of difficult artificial synthesis, high cost and the like of the existing water-soluble epoxide hydrolase inhibitor. The maca extract is prepared into medicines or foods with the effects of resisting inflammation, relieving pain, reducing blood pressure and blood sugar, and protecting cardiovascular system, kidney and nervous system, and has wide market prospect.

Description

Use of maca extract in preparation of medicine or food
Technical Field
The invention relates to the technical field of edible and medicinal application of maca, in particular to the technical field of edible and medicinal application of a maca extract.
Background
Lepidium meyenii belongs to annual or biennial herb of Lepidium of Brassicaceae, and is native to 3500m-4500m south America Andes mountain area of Peruvian sea. Maca is called "Peru ginseng" in south America because of its efficacy comparable to that of ginseng, and is a plant used as both medicine and food. The root of the underground expanded and juicy maca reservoir is radish-like, and is the main edible part with commercial value. In the past 20 years, maca has become more and more well understood and of increasing concern around the world. The natural conditions of western regions in China are suitable for the growth of maca, introduction of seeds is realized in provinces (regions) such as Yunnan, Xinjiang, Jilin and Tibet in China, and the economic and social benefits are good. Researches show that maca has the effects of improving the fertility of people and animals, improving sexual functions, inhibiting enlargement of prostate, resisting fatigue and depression, improving osteoporosis, improving memory and the like.
However, water-soluble antioxidant hydrolase inhibitors have never been reported in the literature in maca extracts. Water-soluble epoxide hydrolase (sEH) is an enzyme capable of metabolizing epoxyfatty acids, which is widely present in mammals, converts endogenous epoxyeicosatrienoic acids (EETs) to dihydroxyeicosatrienoic acids (DHETs). Endogenous EETs are obtained by oxidizing Arachidonic Acid (AA) through certain cytochrome P450 monooxygenases, are important signal molecules in organisms, and have the functions of regulating ion transport, gene expression, vasodilatation and the like. In animals, there are many ways to degrade the EETs, and the sEH metabolizes the EETs into DHETs as the main metabolic pathway, so that the EETs are reduced in concentration and reduced in physiological activity, which may lead to an increase in blood pressure and further affect the functions of kidney and heart. Directly functionally, the water-soluble redox hydrolase inhibitor has various efficacies of reducing blood pressure and blood sugar, protecting the cardiovascular system, the kidney system, the nervous system and the like, and currently, clinical experiments and application of sEH are carried out by a plurality of companies in the United states, but the sEH is a small molecular compound synthesized in a laboratory, and the high-efficiency water-soluble redox hydrolase inhibitor from a natural source is very rare.
Therefore, those skilled in the art are working on developing a highly effective water-soluble epoxide hydrolase inhibitor from natural sources, and related drugs and related functional foods with water-soluble epoxide hydrolase as an action target.
Disclosure of Invention
In view of the above-mentioned defects of the prior art, the technical problem to be solved by the present invention is to obtain a highly effective water-soluble redox hydrolase inhibitor of natural origin, and develop a series of medicines and functional foods around the efficacy of the inhibitor, so as to overcome the problems of high cost, small quantity and small molecule of the artificial synthesis of the water-soluble redox hydrolase inhibitor.
In order to achieve the above object, the present invention provides a use of a maca extract, which is macamide, in the preparation of a medicament or food.
Further, the macamide is a water-soluble epoxide hydrolase inhibitor.
Further, the macamides are
N-benzyl linoleamide;
n-benzyl linolenamide;
n-benzyl arachidonamide;
n-benzyl eicosa-5Z, 8Z,11Z,14Z, 17Z-pentaenamide;
n-3-methoxybenzyl linoleamide;
n-3-methoxybenzyl linolenamide;
n-3-methoxybenzyl arachidonamide;
n-3-methoxybenzyl eicosa-5Z, 8Z,11Z,14Z, 17Z-pentaenamide;
n-3, 4-dimethoxybenzyl linolenamide;
n- (2-phenylethyl) linoleamide;
n- (2-phenylethyl) linolenamide;
any one or a combination of any two or more.
Further, the medicament or food product is an analgesic and or anti-inflammatory product.
Further, the medicament or food product is an analgesic and or anti-inflammatory product.
Further, the function of the drug or food is one or a combination of any of:
protecting the cardiovascular system; the kidney is protected; protecting the nervous system.
Further, the function of the drug or food is one or a combination of any of:
protecting the cardiovascular system; the kidney is protected; protecting the nervous system.
Technical effects
The project firstly clarifies that a class of compounds in maca extract maca amide have the activity of inhibiting water-soluble epoxide hydrolase, proves that the compounds have the function of relieving pain, and can develop a series of medicines, natural medicines and foods taking the inhibiting water-soluble epoxide hydrolase as a target point.
The conception, the specific structure and the technical effects of the present invention will be further described with reference to the accompanying drawings to fully understand the objects, the features and the effects of the present invention.
Drawings
FIG. 1 is a compound structural diagram of N-benzylpalmitamide;
FIG. 2 is a compound structural diagram of N-benzylstearamide;
FIG. 3 is a compound structural diagram of N-benzyl oleamide;
FIG. 4 is a structural diagram of a compound of N-benzyl linoleamide
FIG. 5 is a compound structural diagram of N-benzyl linolenamide
FIG. 6 is a compound structural diagram of N-benzyl arachidonamide
FIG. 7 is a compound structural diagram of N-benzyl eicosa-5Z, 8Z,11Z,14Z, 17Z-pentaenamide
FIG. 8 is a structural diagram of a compound of N-3-methoxybenzyl palmitamide
FIG. 9 is a compound structural diagram of N-3-methoxybenzyl stearamide
FIG. 10 is a compound structural diagram of N-3-methoxybenzyl oleamide
FIG. 11 is a compound structural diagram of N-3-methoxybenzyl linoleamide
FIG. 12 is a compound structural diagram of N-3-methoxybenzyl linolenamide
FIG. 13 is a compound structural diagram of N-3-methoxybenzyl arachidonamide
FIG. 14 is a compound structural diagram of N-3-methoxybenzyl eicosa-5Z, 8Z,11Z,14Z, 17Z-pentaenamide
FIG. 15 is a structural diagram of a compound of N-3, 4-dimethoxybenzylpalmitamide
FIG. 16 is a structural diagram of a compound of N-3, 4-dimethoxybenzyl linoleamide
FIG. 17 is a compound structural diagram of N-3, 4-dimethoxybenzyl linolenamide
FIG. 18 is a structural diagram of a compound of N- (2-phenylethyl) linoleamide
FIG. 19 is a compound structural diagram of N- (2-phenylethyl) linolenamide
FIG. 20 is a graph of experimental data demonstrating the anti-inflammatory analgesic effect of macamides
Detailed Description
Definitions of terms of art:
①IC50(half maximum inhibition concentration) refers to the half inhibitory concentration of the antagonist being measured. It indicates that a drug or substance (inhibitor) is inhibiting half the amount of a biological process (or a substance, such as an enzyme, cellular receptor or microorganism, that is involved in the process). IC (integrated circuit)50The value can be used to measure the ability of a drug to inhibit an enzyme, i.e., the stronger the inhibitory ability, the lower the value.
The CAS Number (CAS Registry Number or CAS Number, CAS Rn, CAS #), also called CAS accession Number, is a unique Number identification Number of a certain substance (compound, polymer material, Biological sequence, mixture or alloy). The lower histochemical Abstract Service (CAS) of the American Chemical society is responsible for assigning a CAS number to each substance appearing in the literature, in order to avoid the trouble of multiple names for chemicals and to facilitate database retrieval. Almost all chemical databases today allow searching with CAS numbers.
③ nM represents units of nmol/L, read as: nanomole per liter;
n is "na", a common unit being nM, 1M ═ 10^ s9nM. M, i.e. "mol/L", is read as: moles per liter.
sEH refers to a water-soluble epoxide hydrolase, water-soluble epoxide hydrolase (sEH).
Example 1
The maca can be extractedA macamide is obtained, the macamide is a water-soluble epoxide hydrolase inhibitor, specifically is N-benzyl palmitamide, a compound structure diagram of the N-benzyl palmitamide is shown in figure 1, and the CAS number of the N-benzyl palmitamide is 74058-71-2. The inventors tested the inhibitory effect of N-benzyl palmitamide on human, rat and mouse water-soluble epoxide hydrolase, where IC is of human sEH50IC of sEH in rat with (nM) of 52450IC of sEH for mouse with (nM) of 37050(nM) is 422. The N-benzyl palmitamide can be used for preparing medicines or foods, and the medicines or the foods have one or more of the following functions: relieving pain, relieving inflammation, protecting cardiovascular system, protecting kidney, and protecting nervous system.
Example 2
Maca can be extracted to obtain maca amide which is a water-soluble epoxide hydrolase inhibitor, specifically N-benzyl stearamide, the structure of the compound of the N-benzyl stearamide is shown in figure 2, and the CAS number of the N-benzyl stearamide is 5327-45-7. The inventors tested the inhibitory effect of N-benzylstearamide on human, rat and mouse water-soluble epoxide hydrolase, where IC is of human sEH50(nM) IC of sEH over 100000 for rats50IC of sEH for mouse with (nM) of 3575550(nM) is 59564. The N-benzyl stearamide can be used for preparing medicines or foods, and the medicines or the foods have one or more of the following functions: relieving pain, relieving inflammation, protecting cardiovascular system, protecting kidney, and protecting nervous system.
Example 3
Maca extracts a macamide which is a water-soluble epoxide hydrolase inhibitor, in particular N-benzyl oleamide, the structure of which is shown in FIG. 3, with CAS number 101762-87-2. The inventors tested the inhibitory effect of N-benzyl oleamide on human, rat and mouse water-soluble epoxide hydrolase, where IC is of human sEH50IC of sEH for rat with (nM) 89350IC of sEH for mouse with (nM) of 19850(nM) is 265. The N-benzyl oleamide may beThe preparation method is used for preparing a medicine or food, and the medicine or the food has one or more of the following functions: relieving pain, relieving inflammation, protecting cardiovascular system, protecting kidney, and protecting nervous system.
Example 4
Maca extracts a macamide which is a water-soluble epoxide hydrolase inhibitor, specifically N-benzyl linoleamide, the structure of which is shown in FIG. 4, and the CAS number of N-benzyl linoleamide is 18286-71-0. The inventors tested the inhibitory effect of N-benzyl linoleamide on human, rat and mouse water-soluble epoxide hydrolases, where IC is of human sEH50IC of sEH in rat with (nM) of 15550IC of sEH for mouse with (nM) of 4150(nM) is 44. The N-benzyl linoleamide can be used for preparing medicines or foods, and the medicines or the foods have one or more of the following functions: relieving pain, relieving inflammation, protecting cardiovascular system, protecting kidney, and protecting nervous system.
The pharmacokinetic parameters of N-benzyl linoleamide in the rat model are as follows:
the IC of rats orally administered N-benzyl linoleamide (dose 100mg/kg rat body weight) reached a peak concentration of 520nM (Cmax 520nM) in blood after 3 hours (Tmax 3h) of 3 hours5011.8 times of the total amount of the compound, and the half-life period is 9 hours (t1/2 is 9 h). The present inventors studied the anti-inflammatory analgesic effect of N-benzyl linoleamide having strong sEH inhibitory effect using LPS-induced inflammatory pain model in rats, and the results are shown in fig. 20, where N-benzyl linoleamide (dose 100mg/kg body weight of rats) orally administered has significant anti-inflammatory analgesic effect.
LPS induced inflammatory pain in the rat paw, as shown in FIG. 20, the rat paw was more sensitive to pain stimulation and the tolerance to pain decreased to around 60% of that before LPS treatment (black filled circles), while oral administration of N-benzyl linoleamide (dose 100mg/kg rat body weight) reduced the LPS induced inflammatory pain in the rat, as compared to the LPS treated model group, the drug group (grey filled triangles) had higher tolerance to pain than the LPS treated group, indicating that N-benzyl linoleamide had anti-inflammatory and analgesic effects. Data are mean ± standard error (N ═ 4), and the tolerance to pain for LPS and pre-drug treated rats was defined as 100%.
Example 5
Maca extracts a macamides which is a water-soluble epoxide hydrolase inhibitor, in particular N-benzyl linolenamide, the structure of which is shown in FIG. 5, with CAS number 883715-18-2. The inventors tested the inhibitory effect of N-benzyl linolenamide on human, rat and mouse water-soluble epoxide hydrolases, where IC is of human sEH50IC of sEH for rat with (nM) of 13450IC of sEH for mouse with (nM) of 2350(nM) is 28. The N-benzyl linolenamide can be used for preparing medicines or foods, and the medicines or the foods have one or more of the following functions: relieving pain, relieving inflammation, protecting cardiovascular system, protecting kidney, and protecting nervous system.
Example 6
Maca can be extracted to obtain maca amide which is a water-soluble epoxide hydrolase inhibitor, specifically N-benzyl arachidonamide, and FIG. 6 shows the structure diagram of the compound of the N-benzyl arachidonamide. The inventors tested the inhibitory effect of N-benzyl arachidonamide on human, rat and mouse water-soluble epoxide hydrolase, where IC is of human sEH50IC of sEH for rat with (nM) 12350IC of sEH for mice with (nM) of 4050(nM) is 50. The N-benzyl peanut tetraenamide can be used for preparing medicines or foods, and the medicines or the foods have one or more of the following functions: relieving pain, relieving inflammation, protecting cardiovascular system, protecting kidney, and protecting nervous system.
Example 7
Maca can be extracted to obtain maca amide which is a water-soluble epoxide hydrolase inhibitor, specifically N-benzyl eicosa-5Z, 8Z,11Z,14Z, 17Z-pentaenamide, and the structure diagram of the compound of the N-benzyl eicosa-5Z, 8Z,11Z,14Z, 17Z-pentaenamide is shown in figure 7. The inventor tests N-benzyl eicosa-5Z, 8Z,11Z,14Z, 17Z-pentaenamide on human and largeInhibition of murine and murine Water-soluble epoxide Hydrolase, where IC is of human sEH50IC of sEH for rat with (nM) of 11150IC of sEH for mouse with (nM) of 2950(nM) is 43. The N-benzyl eicosa-5Z, 8Z,11Z,14Z, 17Z-pentaenamide can be used for preparing medicines or foods, and the medicines or the foods have one or more of the following functions: relieving pain, relieving inflammation, protecting cardiovascular system, protecting kidney, and protecting nervous system.
Example 8
Maca can be used for extracting maca amide which is a water-soluble epoxide hydrolase inhibitor, specifically N-3-methoxybenzyl palmitamide, and figure 8 shows the structure diagram of the compound of the N-3-methoxybenzyl palmitamide, and the CAS number of the N-3-methoxybenzyl palmitamide is 5327-45-7. The inventors tested the inhibitory effect of N-3-methoxybenzyl palmitamide on human, rat and mouse water-soluble epoxide hydrolases, where IC is on human sEH50IC of sEH in rats with (nM) 1607750IC of sEH for mouse with (nM) of 2867650(nM) is 89850. The N-3-methoxybenzyl palmitamide can be used for preparing medicines or foods, and the medicines or the foods have one or more of the following functions: relieving pain, relieving inflammation, protecting cardiovascular system, protecting kidney, and protecting nervous system.
Example 9
Maca can be extracted to obtain maca amide which is a water-soluble epoxide hydrolase inhibitor, specifically N-3-methoxybenzyl stearamide, and FIG. 9 shows the structure of the compound of the N-3-methoxybenzyl stearamide, wherein the CAS number of the N-3-methoxybenzyl stearamide is 883715-21-7. The inventors tested the inhibitory effect of N-3-methoxybenzyl stearamide on human, rat and mouse water soluble epoxide hydrolases, where the IC50(nM) for human sEH was 241 and for rat sEH50IC of sEH for mouse with (nM) of 8450(nM) is 126. The N-3-methoxybenzyl stearamide can be used for preparing medicines or foods, and the medicines or the foods have one or more of the following functions: relieving pain, relieving inflammation, protecting cardiovascular system, protecting kidney, and protecting skinProtecting the nervous system.
Example 10
Maca can be extracted to obtain maca amide which is a water-soluble epoxide hydrolase inhibitor, specifically N-3-methoxybenzyl oleamide, the structure diagram of the compound of the N-3-methoxybenzyl oleamide is shown in figure 10, and the CAS number of the N-3-methoxybenzyl oleamide is 74058-71-2. The inventors tested the inhibitory effect of N-3-methoxybenzyl oleamide on human, rat and mouse water-soluble epoxide hydrolases, where IC is on human sEH50IC of sEH in rat with (nM) of 24150IC of sEH for mouse with (nM) of 8450(nM) is 126. The N-3-methoxybenzyl oleamide can be used for preparing medicines or foods, and the medicines or the foods have one or more of the following functions: relieving pain, relieving inflammation, protecting cardiovascular system, protecting kidney, and protecting nervous system.
Example 11
Maca can be extracted to obtain maca amide which is a water-soluble epoxide hydrolase inhibitor, specifically N-3-methoxybenzyl linoleamide, and FIG. 11 shows the structure of the compound of the N-3-methoxybenzyl linoleamide. The inventors tested the inhibitory effect of N-3-methoxybenzyl linoleamide on human, rat and mouse water-soluble epoxide hydrolases, where IC is on human sEH50IC of sEH for rat with (nM) 9250IC of sEH for mouse with (nM) of 4350(nM) is 38. The N-3-methoxybenzyl linoleamide can be used for preparing medicines or foods, and the medicines or the foods have one or more of the following functions: relieving pain, relieving inflammation, protecting cardiovascular system, protecting kidney, and protecting nervous system.
Example 12
Maca can be extracted to obtain maca amide which is a water-soluble epoxide hydrolase inhibitor, specifically N-3-methoxybenzyl linolenamide, and a compound structure diagram of the N-3-methoxybenzyl linolenamide is shown in figure 12. The inventors tested the inhibitory effect of N-3-methoxybenzyl linolenamide on human, rat and mouse water-soluble epoxide hydrolases, where the sE is humanIC of H50IC of sEH for rat with (nM) of 7650IC of sEH for mouse with (nM) of 9.350(nM) was 27. The N-3-methoxybenzyl linolenamide can be used for preparing medicines or foods, and the medicines or the foods have one or more of the following functions: relieving pain, relieving inflammation, protecting cardiovascular system, protecting kidney, and protecting nervous system.
Example 13
Maca can be extracted to obtain maca amide which is a water-soluble epoxide hydrolase inhibitor, specifically N-3-methoxybenzyl arachidonamide, and FIG. 13 shows the structure of the compound of the N-3-methoxybenzyl arachidonamide. The inventors tested the inhibitory effect of N-3-methoxybenzyl arachidonamide on human, rat and mouse water-soluble epoxide hydrolases, where IC is on human sEH50IC of sEH in rat with (nM) of 5550IC of sEH for mice with (nM) of 2250(nM) is 73. The N-3-methoxybenzyl arachidonamide can be used for preparing medicines or foods, and the medicines or the foods have one or more of the following functions: relieving pain, relieving inflammation, protecting cardiovascular system, protecting kidney, and protecting nervous system.
Example 14
Maca can be extracted to obtain maca amide which is a water-soluble epoxide hydrolase inhibitor, specifically N-3-methoxybenzyl eicosa-5Z, 8Z,11Z,14Z, 17Z-pentaenamide, and a compound structure diagram of the N-3-methoxybenzyl eicosa-5Z, 8Z,11Z,14Z, 17Z-pentaenamide is shown in figure 14. The inventors tested the inhibitory effect of N-3-methoxybenzyl eicosa-5Z, 8Z,11Z,14Z, 17Z-pentaenamide on human, rat and mouse water-soluble epoxide hydrolases, where IC is on human sEH50IC of sEH for rat with (nM) 6350(nM) 18.6, IC of sEH for mice50(nM) is 49. The N-3-methoxybenzyl eicosane-5Z, 8Z,11Z,14Z, 17Z-pentaenamide can be used for preparing medicines or foods, and the medicines or the foods have one or more of the following functions: relieving pain, relieving inflammation, protecting cardiovascular system, protecting kidney, and protecting nervous system.
Example 15
Maca can be extracted to obtain maca amide which is a water-soluble epoxide hydrolase inhibitor, specifically N-3, 4-dimethoxybenzyl palmitamide, the structure diagram of the compound of the N-3, 4-dimethoxybenzyl palmitamide is shown in figure 15, and the CAS number of the N-3, 4-dimethoxybenzyl palmitamide is 74058-71-2. The inventors tested the inhibitory effect of N-3, 4-dimethoxybenzyl-palmitamide on human, rat and mouse water-soluble epoxide hydrolases, where IC is on human sEH50(nM) 7059, IC of sEH in rat50IC of sEH for mouse with (nM) of 1591050(nM) is greater than 100000. The N-3, 4-dimethoxy benzyl palmitamide can be used for preparing medicines or foods, and the medicines or the foods have one or more of the following functions: relieving pain, relieving inflammation, protecting cardiovascular system, protecting kidney, and protecting nervous system.
Example 16
Maca can be extracted to obtain maca amide which is a water-soluble epoxide hydrolase inhibitor, specifically N-3, 4-dimethoxybenzyl linoleamide, the compound structure diagram of the N-3, 4-dimethoxybenzyl linoleamide is shown in figure 16, and the CAS number of the N-3, 4-dimethoxybenzyl linoleamide is 74058-71-2. The inventors tested the inhibitory effect of N-3, 4-dimethoxybenzyl linoleamide on human, rat and mouse water-soluble epoxide hydrolases, where IC is on human sEH50IC of sEH in rats with (nM) of 10450IC of sEH for mouse with (nM) of 11150(nM) is 148. The N-3, 4-dimethoxy benzyl linoleamide can be used for preparing medicines or foods, and the medicines or the foods have one or more of the following functions: relieving pain, relieving inflammation, protecting cardiovascular system, protecting kidney, and protecting nervous system.
Example 17
Maca can be extracted to obtain maca amide which is a water-soluble epoxide hydrolase inhibitor, specifically N-3, 4-dimethoxybenzyl linolenamide, and a compound structure diagram of the N-3, 4-dimethoxybenzyl linolenamide is shown in figure 17. The inventors tested N-3, 4-dimethoxybenzylInhibition of human, rat and mouse water-soluble epoxide hydrolases by linolenamides, in which IC is of human sEH50IC of sEH in rat with (nM) of 8450IC of sEH for mouse with (nM) 9050(nM) is 122. The N-3, 4-dimethoxy benzyl linolenamide can be used for preparing medicines or foods, and the medicines or the foods have one or more of the following functions: relieving pain, relieving inflammation, protecting cardiovascular system, protecting kidney, and protecting nervous system.
Example 18
Maca extracts a macamide which is a water-soluble epoxide hydrolase inhibitor, specifically N- (2-phenylethyl) linoleamide, and fig. 18 shows the structure of the compound of N- (2-phenylethyl) linoleamide. The inventors tested the inhibitory effect of N- (2-phenylethyl) linoleamide on water-soluble epoxide hydrolase of human, rat and mouse, wherein IC of sEH of human50IC of sEH for rat with (nM) of 2850IC of sEH for mouse with (nM) of 3350(nM) was 91. The N- (2-phenylethyl) linoleamide can be used for preparing medicines or foods, and the medicines or the foods have one or more of the following functions: relieving pain, relieving inflammation, protecting cardiovascular system, protecting kidney, and protecting nervous system.
Example 19
Maca extracts a macamide which is a water-soluble epoxide hydrolase inhibitor, specifically N- (2-phenylethyl) linolenamide, and fig. 19 shows the structure of the compound of N- (2-phenylethyl) linolenamide, which has CAS number 74058-71-2. The inventors tested the inhibitory effect of N- (2-phenylethyl) linolenamide on human, rat and mouse water-soluble epoxide hydrolases, where IC was on human sEH50IC of sEH in rat with (nM) of 52450IC of sEH for mouse with (nM) of 37050(nM) is 422. The N- (2-phenethyl) linolenamide can be used for preparing medicines or foods, and the medicines or the foods have one or more of the following functions: relieving pain, relieving inflammation, protecting cardiovascular system, protecting kidney, and protecting nervous system.
Example 20
Maca can be extracted to obtain maca amide, and the maca amide can be used for preparing medicines or foods, and the medicines or the foods have one or more of the following functions: relieving pain, relieving inflammation, protecting cardiovascular system, protecting kidney, and protecting nervous system.
Example 21
Maca can extract a water-soluble epoxide hydrolase inhibitor, which can be used for preparing a drug or a food, wherein the drug or the food has one or more of the following functions: relieving pain, relieving inflammation, protecting cardiovascular system, protecting kidney, and protecting nervous system.
The foregoing detailed description of the preferred embodiments of the invention has been presented. It should be understood that numerous modifications and variations could be devised by those skilled in the art in light of the present teachings without departing from the inventive concepts. Therefore, the technical solutions available to those skilled in the art through logic analysis, reasoning and limited experiments based on the prior art according to the concept of the present invention should be within the scope of protection defined by the claims.

Claims (7)

1. Use of a maca extract in the preparation of a medicament or food product, characterised in that the extract is macamide.
2. The use according to claim 1, wherein the macamide is a water-soluble epoxide hydrolase inhibitor.
3. Use according to claim 1 or 2, characterized in that the macamide is:
n-benzyl linoleamide;
n-benzyl linolenamide;
n-benzyl arachidonamide;
n-benzyl eicosa-5Z, 8Z,11Z,14Z, 17Z-pentaenamide;
n-3-methoxybenzyl linoleamide;
n-3-methoxybenzyl linolenamide;
n-3-methoxybenzyl arachidonamide;
n-3-methoxybenzyl eicosa-5Z, 8Z,11Z,14Z, 17Z-pentaenamide;
n-3, 4-dimethoxybenzyl linolenamide;
n- (2-phenylethyl) linoleamide;
n- (2-phenylethyl) linolenamide;
any one or a combination of any two or more.
4. Use according to claim 1 or 2, wherein the medicament or food product is an analgesic and or anti-inflammatory product.
5. Use according to claim 3, wherein the medicament or food product is an analgesic and or anti-inflammatory product.
6. Use according to claim 1 or 2, wherein the function of the medicament or food product is one or a combination of any of the following:
protecting the cardiovascular system; the kidney is protected; protecting the nervous system.
7. Use according to claim 3, wherein the function of the medicament or food product is one or a combination of any of:
protecting the cardiovascular system; the kidney is protected; protecting the nervous system.
CN202010510452.XA 2020-06-08 2020-06-08 Use of maca extract in preparation of medicine or food Pending CN113827630A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010510452.XA CN113827630A (en) 2020-06-08 2020-06-08 Use of maca extract in preparation of medicine or food

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010510452.XA CN113827630A (en) 2020-06-08 2020-06-08 Use of maca extract in preparation of medicine or food

Publications (1)

Publication Number Publication Date
CN113827630A true CN113827630A (en) 2021-12-24

Family

ID=78963560

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010510452.XA Pending CN113827630A (en) 2020-06-08 2020-06-08 Use of maca extract in preparation of medicine or food

Country Status (1)

Country Link
CN (1) CN113827630A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104739916A (en) * 2015-04-21 2015-07-01 中国科学院过程工程研究所 Alpha-glucosidase active inhibitor as well as preparation method and application thereof
CN106974955A (en) * 2017-04-12 2017-07-25 云南省药物研究所 A kind of Maca extract for improving sex dysfunction and its preparation method and application
CN110041291A (en) * 2018-01-15 2019-07-23 北京采瑞医药科技研究院有限公司 A kind of novel macamide derivative and preparation method thereof
CN113784627A (en) * 2019-04-17 2021-12-10 国际香料和香精公司 Aromatic alkylamides and methods of use thereof in taste modulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104739916A (en) * 2015-04-21 2015-07-01 中国科学院过程工程研究所 Alpha-glucosidase active inhibitor as well as preparation method and application thereof
CN106974955A (en) * 2017-04-12 2017-07-25 云南省药物研究所 A kind of Maca extract for improving sex dysfunction and its preparation method and application
CN110041291A (en) * 2018-01-15 2019-07-23 北京采瑞医药科技研究院有限公司 A kind of novel macamide derivative and preparation method thereof
CN113784627A (en) * 2019-04-17 2021-12-10 国际香料和香精公司 Aromatic alkylamides and methods of use thereof in taste modulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
周严严等: "药用植物玛咖研究新进展", 《中国中药杂志》 *
邵炎等: "玛咖特征活性成分研究进展", 《天然产物研究与开发》 *

Similar Documents

Publication Publication Date Title
Ramamoorthy et al. Effect of supplementation of Spirulina on hypercholesterolemic patients
Basu et al. Evaluation of nitric oxide scavenging activity, in vitro and ex vivo, of selected medicinal plants traditionally used in inflammatory diseases
Yang et al. Amygdalin suppresses lipopolysaccharide-induced expressions of cyclooxygenase-2 and inducible nitric oxide synthase in mouse BV2 microglial cells
Lele Beyond reverse pharmacology: Mechanism-based screening of Ayurvedic drugs
US10603270B2 (en) Skin care compositions and methods of use thereof
CN106333869B (en) Skin care product with whitening and freckle removing effects and preparation method thereof
Sun et al. Protostane-type triterpenoids as natural soluble epoxide hydrolase inhibitors: Inhibition potentials and molecular dynamics
Tekulu et al. Anti-inflammatory and anti-nociceptive property of Capparis tomentosa Lam. root extracts
Lin et al. Antifatigue properties of tanshinone IIA in mice subjected to the forced swimming test
Ford-Hutchinson Leukotriene B4 and neutrophil function: a review
Lee Anti-metastatic and anti-inflammatory effects of matrix metalloproteinase inhibition by ginsenosides
CN113827630A (en) Use of maca extract in preparation of medicine or food
JP2019520368A (en) Composition useful for preventing and / or treating inflammation and pain of bone joints and cartilage damage
CN100486971C (en) Compound 2,3,4,6,8-pentamethoxyl-dibenzofuran and its use
CN101757056A (en) Extract of yangtao actinidia root and preparation method and applications thereof
US8491888B2 (en) Highly absorbable coenzyme Q10 composition and method of producing same
CN1977795A (en) Use of total cistanchis glycoside for inhibiting skin pigment deposition and whitening
CN109528862A (en) A kind of Chinese medical extract, preparation method and application
EP2851079A1 (en) Pharmaceutical composition containing human cyclooxygenase and doxorubicin or doxorubicin analogue, preparation method therefor and use thereof in preparing drugs
Gopalakrishnan Insignificant antifungal activity of plant extracts on Malassezia furfur
AU2019100730A4 (en) Use of Composition of Sunflower Head, Gorgon Euryale Seed and Kudzuvine Root in Lowering Uric Acid and Repair of Liver and Kidney Injury
Ashida et al. A pilot study: Effects of dietary supplementation with α-linolenic acid-enriched perilla seed oil on bronchial asthma
Walker et al. Regulation of acetylcholinesterase in chick muscle cultures after treatment with diisopropylphosphorofluoridate: ribonucleic acid and protein synthesis
Bawazeer et al. In vitro antiglycation and lipoxygenase inhibition of naphthoquinones isolated from Diospyros lotus Linn
Tamaoki et al. Z/ZYPH/Fructus, a Constituent of Antiasthmatic Herbal Medicine, Stimulates Airway Epithelial Ciliary Motility Through Nitric Oxide Generation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20211224